IL13 and COVID-19: Following anti-IL13 treatment in patients with severe COVID-19, Donlan et al. discovered that Arg1 expression was substantially downregulated, further suggesting the involvement of IL-13 in the pathogenesis of pulmonary fibrosis secondary to COVID-19 infection [22].